Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Performance

Bio-Path stock opened at $0.14 on Friday. Bio-Path has a one year low of $0.12 and a one year high of $4.55. The business has a 50 day simple moving average of $0.16 and a 200 day simple moving average of $0.63.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.